TITLE

Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin

AUTHOR(S)
Moretti, Laura V.; Montalvo, Rolf O.
PUB. DATE
December 2009
SOURCE
American Journal of Health-System Pharmacy;12/1/2009, Vol. 66 Issue 23, p2123
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The case of a patient who experienced elevated International Normalized Ratio (INR) values and hemorrhage after sorafenib was added to his warfarin regimen is presented. Summary. A 70-year-old Caucasian man with a history of hypertension, congestive heart failure, gastroesophageal reflux disease, chronic obstructive pulmonary disease, and chronic hepatitis C was treated with warfarin for anticoagulation subsequent to atrial fibrillation. He began anticoagulation management by a clinical pharmacist in April 2007 and was stabilized on warfarin 36 mg weekly. He was diagnosed with hepatocellular carcinoma in June 2007 and began treatment with sorafenib 200 mg daily in September 2007. The patient arrived at the emergency room one month later with a prothrombin time (PT) of 84.8 and an INR value of 39.5. He was admitted for lower-extremity hemorrhage and diagnosed with warfarin toxicity. Sorafenib was discontinued, and warfarin was held during this hospital stay. The patient was discharged on warfarin 3 mg daily. In November, warfarin was increased to 36 mg weekly, and his INR values stabilized. In late November, he was restarted on sorafenib 200 mg daily presumably due to multiple new hepatic hypodense lesions indicating progression of the metastatic disease. Approximately two weeks later, the patient's INR value increased to 4.7. Sorafenib was discontinued permanently. Both the Naranjo et al. probability scale score and the drug interaction probability scale score suggest that there was a probable interaction between warfarin and sorafenib. Conclusion. A 70-year-old man diagnosed with hepatocellular carcinoma experienced an increase in INR values after the addition of sorafenib to his warfarin regimen.
ACCESSION #
45238699

 

Related Articles

  • Risk of Bleeding with Warfarin Therapy for Atrial Fibrillation. Dimarco, John P. // Clinical Cardiology Alert;Jan2013, Vol. 32 Issue 1, p5 

    The author comments on a study by T. Gomes and colleagues on rates of hemorrhage during warfarin therapy for atrial fibrillation (AF), which revealed that the risk of hemorrhage is high in patients with AF on warfarin therapy. He opines that the rate of bleeding is very high during the first...

  • Dabigatran vs warfarin: Less bleeding?  // Clinical Cardiology Alert;Nov2009 Clinical Briefs, p21 

    The article discusses research on the efficacy of dabigatran (DAB) and warfarin (WRF) against bleeding in patients with atrial fibrillation (AF). It references a study by S. J. Connolly et al published in a 2009 issue of the "New England Journal of Medicine." According to the study, DAB can be...

  • Dabigatran vs warfarin: Less bleeding? Kuritzky, Louis // Primary Care Reports;Nov2009 Primary Care, p21 

    The article discusses research on the efficacy of dabigatran (DAB) and warfarin (WRF) against bleeding in patients with atrial fibrillation (AF). It references a study by S. J. Connolly et al published in a 2009 issue of the "New England Journal of Medicine." According to the study, DAB can be...

  • Dabigatran vs warfarin: Less bleeding?  // Clinical Oncology Alert;Nov2009 Supplement, p21 

    The article discusses research on the efficacy of dabigatran (DAB) and warfarin (WRF) against bleeding in patients with atrial fibrillation (AF). It references a study by S. J. Connolly et al published in a 2009 issue of the "New England Journal of Medicine." According to the study, DAB can be...

  • Dabigatran vs warfarin: Less bleeding? Kuritzky, Louis // Neurology Alert;Nov2009 Primary Care, p21 

    The article discusses research on the efficacy of dabigatran (DAB) and warfarin (WRF) against bleeding in patients with atrial fibrillation (AF). It references a study by S. J. Connolly et al published in a 2009 issue of the "New England Journal of Medicine." According to the study, of DAB can...

  • Risk of Bleeding with Warfarin Therapy for Atrial Fibrillation. DiMarco, John P. // Internal Medicine Alert;2/28/2013, Vol. 35 Issue 4, p25 

    The authors conclude that in a large cohort of older patients with atrial fibrillation, hemorrhage is common during both the first 30 days and subsequent months of warfarin therapy, and is related to risk factors in the CHADS2 score and also to age.

  • The Unmet Needs in the Management of Stroke Prevention in Atrial Fibrillation. Miller, Michael // Journal of Managed Care Medicine;2013, Vol. 16 Issue 3, p58 

    No abstract available.

  • The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation. Singer, Daniel E.; Yuchiao Chang; Fang, Margaret C.; Borowsky, Leila H.; Pomernacki, Niela K.; Udaltsova, Natalia; Go, Alan S. // Annals of Internal Medicine;9/1/2009, Vol. 151 Issue 5, p297 

    Background: Guidelines recommend warfarin use in patients with atrial fibrillation solely on the basis of risk for ischemic stroke without antithrombotic therapy. These guidelines rely on ischemic stroke rates observed in older trials and do not explicitly account for increased risk for...

  • Benefit-Risk Assessment of Dabigatran in the Treatment of Stroke Prevention in Non-Valvular Atrial Fibrillation. Meyer dos Santos, Sascha; Harder, Sebastian // Drug Safety;May2014, Vol. 37 Issue 5, p295 

    Non-valvular atrial fibrillation (NVAF) is the most common clinically significant cardiac arrhythmia and is a common cause of stroke. The direct thrombin inhibitor dabigatran etexilate is approved for a variety of indications requiring anticoagulation, including stroke prevention in NVAF....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics